KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sarepta Therapeutics (SRPT) EBIT Margin (2017 - 2025)

Sarepta Therapeutics (SRPT) has 12 years of EBIT Margin data on record, last reported at 25.14% in Q2 2025.

  • For Q2 2025, EBIT Margin rose 2534.0% year-over-year to 25.14%; the TTM value through Jun 2025 reached 43.14%, up 4013.0%, while the annual FY2024 figure was 191.27%, 21281.0% up from the prior year.
  • EBIT Margin reached 25.14% in Q2 2025 per SRPT's latest filing, up from 15.61% in the prior quarter.
  • Across five years, EBIT Margin topped out at 25.14% in Q2 2025 and bottomed at 583.93% in Q3 2022.
  • Average EBIT Margin over 5 years is 76.41%, with a median of 54.47% recorded in 2023.
  • Peak YoY movement for EBIT Margin: crashed -56918bps in 2022, then surged 49128bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 94.5% in 2021, then soared by 33bps to 63.15% in 2022, then surged by 108bps to 5.31% in 2023, then crashed by -394bps to 15.61% in 2024, then surged by 261bps to 25.14% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 25.14% in Q2 2025, 15.61% in Q4 2024, and 2.03% in Q3 2024.